Senti Biosciences (SNTI) Preferred Stock Liabilities (2021 - 2024)

Senti Biosciences has reported Preferred Stock Liabilities for 3 years, with the latest figure at $25.1 million in Q4 2024.

• For the quarter ending Q4 2024, Preferred Stock Liabilities changed N/A year-over-year to $25.1 million; the trailing twelve-month figure through Dec 2024 stood at $25.1 million (changed N/A YoY), and the FY2024 full-year result was $25.1 million, changed N/A from the prior year.
• Preferred Stock Liabilities for Q4 2024 stood at $25.1 million, down from $171.8 million in the prior quarter.
• The five-year high for Preferred Stock Liabilities was $171.8 million in Q2 2021, with the low at $25.1 million in Q4 2024.
• Average Preferred Stock Liabilities over 3 years is $134.1 million, with a median of $171.8 million recorded in 2021.
• Peak annual rise in Preferred Stock Liabilities reached 86.86% in 2022, while the deepest fall reached 86.86% in 2022.
• Tracing SNTI's Preferred Stock Liabilities over 3 years: stood at $171.8 million in 2021, then changed by 0.0% to $171.8 million in 2022, then tumbled by 85.39% to $25.1 million in 2024.
• The last three Preferred Stock Liabilities figures came in at $25.1 million (Q4 2024), $171.8 million (Q1 2022), and $171.8 million (Q4 2021), per Business Quant data.

Peer Comparison